Purification of protein therapeutics via high-affinity supramolecular host–guest interactions

Jaeyeon An,Sungwan Kim,Annadka Shrinidhi,Junghyun Kim,Hasanul Banna,Gihyun Sung,Kyeng Min Park,Kimoon Kim
DOI: https://doi.org/10.1038/s41551-020-0589-7
IF: 28.1
2020-07-20
Nature Biomedical Engineering
Abstract:Efficient purification is crucial to providing large quantities of recombinant therapeutic proteins, such as monoclonal antibodies and cytokines. However, affinity techniques for manufacturing protein therapeutics that use biomolecule-conjugated agarose beads that harness specific biomolecular interactions suffer from issues related to protein denaturation, contamination and the need to maintain biomolecule-specific conditions for efficient protein capture. Here, we report a versatile and scalable method for the purification of recombinant protein therapeutics. The method exploits the high-affinity and controllable host–guest interactions between cucurbit[7]uril (CB[7]) and selected guests such as adamantylammonium. We show that the Herceptin (the brand name of trastuzumab, a monoclonal antibody drug used to treat breast cancer) and the much smaller cytokine interferon α-2a can be purified by site-specifically tagging them with adamantylammonium using the enzyme sortase A, followed by high-affinity binding with CB[7]-conjugated agarose beads and the recovery of the protein using a guest with a stronger affinity for CB[7]. The thermal and chemical stability of CB[7] beads and their scalability, recyclability and low cost may also make them advantageous for the manufacturing of biosimilars.
engineering, biomedical
What problem does this paper attempt to address?